Bringing down the wall of the Mycobacterium tuberculosis fortress: Old and new inhibitors of mycolic acid biosynthesis

Current Respiratory Medicine Reviews

Volumn 5, Issue 3, 2009, Pages 190-200

  Morbidoni, Héctor R ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Enoyl ACP reductase; Ethionamide; Isoniazid; Isoxyl; Mycolic acid biosynthesis; Thiacetazone; Tuberculosis

Indexed keywords

2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ARABINOGALACTAN; BACTERIAL PROTEIN; DIHYDROFOLATE REDUCTASE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ETHA PROTEIN; ETHIONAMIDE; FATTY ACID SYNTHASE; FATTY ACID SYNTHETASE TYPE II; INHA PROTEIN; ISONIAZID; KATG PROTEIN; MYCOLIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEPTIDOGLYCAN; PYRAZINAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RIFAMPICIN; THIOACETAZONE; TIOCARLIDE; TRICLOSAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GENETICS; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG ACTIVATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; FATTY ACID SYNTHESIS; HUMAN; LIPID COMPOSITION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STAPHYLOCOCCUS AUREUS; TUBERCULOSIS;

EID: 74849123475     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339809788922397     Document Type: Review

References (150)

1. World Health Organization. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. WHO/HTM/TB/2008.393. 2009.
2. Davies PD. The role of DOTS in tuberculosis treatment and control. Am J Respir Med 2003; 2(3): 203-9.
3. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352(9144): 1886-91.
4. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185(8): 1197-202.
5. Espinal MA. The global situation of MDR-TB. Tuberculosis (Edinb ) 2003; 83(1-3): 44-51.
6. Espinal MA, Dye C. Can DOTS control multidrug-resistant tuberculosis? Lancet 2005; 365(9466): 1206-9.
7. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med 2007; 356(7): 656-9.
8. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373(9678): 1861-73.
9. Minnikin DE, Kremer L, Dover LG, Besra GS. The methylbranched fortifications of Mycobacterium tuberculosis. Chem Biol 2002; 9(5): 545-53.
10. Daffe M, Draper P. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 1998; 39: 131-203.
11. Laneelle G, Daffe M. Mycobacterial cell wall and pathogenicity: a lipodologist's view. Res Microbiol 1991; 142(4): 433-7.
12. Wood WI, Peterson DO, Bloch K. Subunit structure of Mycobacterium smegmatis fatty acid synthetase. Evidence for identical multifunctional polypeptide chains. J Biol Chem 1978; 253(8): 2650-6.
13. Bloch K. Fatty acid synthases from Mycobacterium phlei. Methods Enzymol 1975; 35: 84-90.
14. Etienne G, Malaga W, Laval F, Lemassu A, Guilhot C, Daffe M. Identification of the polyketide synthase involved in the biosynthesis of the surface-exposed lipooligosaccharides in mycobacteria. J Bacteriol 2009; 191(8): 2613-21.
15. Constant P, Perez E, Malaga W, et al. Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex. Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frameshift mutation in the pks15/1 gene. J Biol Chem 2002; 277(41): 38148-58.
16. Gokhale RS, Saxena P, Chopra T, Mohanty D. Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids. Nat Prod Rep 2007; 24(2): 267-77.
17. Bhatt K, Gurcha SS, Bhatt A, Besra GS, Jacobs WR, Jr. Two polyketide-synthase-associated acyltransferases are required for sulfolipid biosynthesis in Mycobacterium tuberculosis. Microbiology 2007; 153(Pt 2): 513-20.
18. Dubey VS, Sirakova TD, Kolattukudy PE. Disruption of msl3 abolishes the synthesis of mycolipanoic and mycolipenic acids required for polyacyltrehalose synthesis in Mycobacterium tuberculosis H37Rv and causes cell aggregation. Mol Microbiol 2002; 45(5): 1451-9.
19. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994; 123(1-2): 11-8.
20. Villeneuve C, Gilleron M, Maridonneau-Parini I, Daffe M, starie-Dequeker C, Etienne G. Mycobacteria use their surface-exposed glycolipids to infect human macrophages through a receptor-dependent process. J Lipid Res 2005; 46(3): 475-83.
21. Vergne I, Daffe M. Interaction of mycobacterial glycolipids with host cells. Front Biosci 1998; 3: d865-d876.
22. Ortalo-Magne A, Lemassu A, Laneelle MA, et al. Identification of the surface-exposed lipids on the cell envelopes of Mycobacterium tuberculosis and other mycobacterial species. J Bacteriol 1996; 178(2): 456-61.
23. Daffe M, Papa F, Laszlo A, David HL. Glycolipids of recent clinical isolates of Mycobacterium tuberculosis: chemical characterization and immunoreactivity. J Gen Microbiol 1989; 135(10): 2759-66.
24. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb ) 2003; 83(1-3): 91-7.
25. Chatterjee D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr Opin Chem Biol 1997; 1(4): 579-88.
26. McNeil MR, Brennan PJ. Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Res Microbiol 1991; 142(4): 451-63.
27. Besra GS, Khoo KH, McNeil MR, Dell A, Morris HR, Brennan PJ. A new interpretation of the structure of the mycolylarabinogalactan complex of Mycobacterium tuberculosis as revealed through characterization of oligoglycosylalditol fragments by fast-atom bombardment mass spectrometry and 1H nuclear magnetic resonance spectroscopy. Biochemistry 1995; 34(13): 4257-66.
28. McNeil M, Daffe M, Brennan PJ. Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls. J Biol Chem 1990; 265(30): 18200-6.
29. Alderwick LJ, Birch HL, Mishra AK, Eggeling L, Besra GS. Structure, function and biosynthesis of the Mycobacterium tuberculosis cell wall: arabinogalactan and lipoarabinomannan assembly with a view to discovering new drug targets. Biochem Soc Trans 2007; 35(Pt 5): 1325-8.
30. Barry CE, Crick DC, McNeil MR. Targeting the formation of the cell wall core of M. tuberculosis. Infect Disord Drug Targets 2007; 7(2): 182-202.
31. Crick DC, Mahapatra S, Brennan PJ. Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiology 2001; 11(9): 107R-18R.
32. Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol 2004; 53(2): 391-403.
33. Chatterjee D, Bozic CM, McNeil M, Brennan PJ. Structural features of the arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis. J Biol Chem 1991; 266(15): 9652-60.
34. Dao DN, Kremer L, Guerardel Y, et al. Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect Immun 2004; 72(4): 2067-74.
35. Hunter RL, Venkataprasad N, Olsen MR. The role of trehalose dimycolate (cord factor) on morphology of virulent M. tuberculosis in vitro. Tuberculosis (Edinb ) 2006; 86(5): 349-56.
36. Glickman MS, Cox JS, Jacobs WR, Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5(4): 717-27.
37. Harland CW, Rabuka D, Bertozzi CR, Parthasarathy R. The Mycobacterium tuberculosis virulence factor trehalose dimycolate imparts desiccation resistance to model mycobacterial membranes. Biophys J 2008; 94(12): 4718-24.
38. Takimoto H, Maruyama H, Shimada KI, Yakabe R, Yano I, Kumazawa Y. Interferon-gamma independent formation of pulmonary granuloma in mice by injections with trehalose dimycolate (cord factor), lipoarabinomannan and phosphatidylinositol mannosides isolated from Mycobacterium tuberculosis. Clin Exp Immunol 2006; 144(1): 134-41.
39. Indrigo J, Hunter RL, Jr., Actor JK. Cord factor trehalose 6,6'-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology 2003; 149(Pt 8): 2049-59.
40. Bloch H, Noll H. Studies on the virulence of Tubercle bacilli; the effect of cord factor on murine tuberculosis. Br J Exp Pathol 1955; 36(1): 8-17.
41. Rao V, Fujiwara N, Porcelli SA, Glickman MS. Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med 2005; 201(4): 535-43.
42. Rao V, Gao F, Chen B, Jacobs WR, Jr., Glickman MS. Transcyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis -induced inflammation and virulence. J Clin Invest 2006; 116(6): 1660-7.
43. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb ) 2004; 84(1-2): 29-44.
44. Daniel J, Deb C, Dubey VS, et al. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol 2004; 186(15): 5017-30.
45. Veyron-Churlet R, Bigot S, Guerrini O, et al. The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. J Mol Biol 2005; 353(4): 847-58.
46. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev 2005; 18(1): 81-101.
47. Fox HH. The chemical approach to the control of tuberculosis. Science 1952; 116(3006): 129-34.
48. Gangadharam PR, Harold FM, Schaefer WB. Selective inhibition of nucleic acid synthesis in Mycobacterium tuberculosis by isoniazid. Nature 1963; 198: 712-4.
49. Schaefer WB. Effect of isoniazid on the dehydrogenase activity of Mycobacterium tuberculosis. J Bacteriol 1960; 79: 236-45.
50. Winder FG, Brennan PJ, McDonnell I. Effects of isoniazid on the composition of mycobacteria, with particular reference to soluble carbohydrates and related substances. Biochem J 1967; 104(2): 385-93.
51. Winder FG, Rooney SA. The effects of isoniazid on the carbohydrates of Mycobacterium tuberculosis BCG. Biochem J 1970; 117(2): 355-68.
52. Winder FG, Collins PB. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J Gen Microbiol 1970; 63(1): 41-8.
53. Takayama K, Schnoes HK, Armstrong EL, Boyle RW. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res 1975; 16(4): 308-17.
54. Takayama K, Wang L, David HL. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1972; 2(1): 29-35.
55. Middlebrook G, Cohn ML. Attenuation of isoniazid-resistant mutants of tubercle bacilli and host hypersensitivity to tuberculin. Proc Soc Exp Biol Med 1955; 88(4): 568-71.
56. Middlebrook G, Dressler SH. Isoniazid resistance. Lancet 1955; 268(6865): 669-70.
57. Middlebrook G, Cohn ML, Schaefer WB. Studies on isoniazid and tubercle bacilli. III. The isolation, drug-susceptibility, and catalase-testing of tubercle bacilli from isoniazid-treated patients. Am Rev Tuberc 1954; 70(5): 852-72.
58. Heym B, Cole ST. Isolation and characterization of isoniazid-resistant mutants of Mycobacterium smegmatis and M. aurum. Res Microbiol 1992; 143(7): 721-30.
59. Heym B, Saint-Joanis B, Cole ST. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuber Lung Dis 1999; 79(4): 267-71.
60. Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15(2): 235-45.
61. Heym B, Zhang Y, Poulet S, Young D, Cole ST. Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol 1993; 175(13): 4255-9.
62. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263(5144): 227-30.
63. Mdluli K, Slayden RA, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280(5369): 1607-10.
64. Slayden RA, Lee RE, Barry CE, III. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol Microbiol 2000; 38(3): 514-25.
65. Slayden RA, Barry CE, III. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2002; 82(4-5): 149-60.
66. Basso LA, Zheng R, Musser JM, Jacobs WR, Jr., Blanchard JS. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 1998; 178(3): 769-75.
67. Marcinkeviciene JA, Magliozzo RS, Blanchard JS. Purification and characterization of the Mycobacterium smegmatis catalase-peroxidase involved in isoniazid activation. J Biol Chem 1995; 270(38): 22290-5.
68. Quemard A, Sacchettini JC, Dessen A, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995; 34(26): 8235-41.
69. Dessen A, Quemard A, Blanchard JS, Jacobs WR, Jr., Sacchettini JC. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995; 267(5204): 1638-41.
70. Vilcheze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006; 12(9): 1027-9.
71. Vilcheze C, Morbidoni HR, Weisbrod TR, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 2000; 182(14): 4059-67.
72. Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Jr., Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279(5347): 98-102.
73. Dessen A, Quemard A, Blanchard JS, Jacobs WR, Jr., Sacchettini JC. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995; 267(5204): 1638-41.
74. Vilcheze C, Weisbrod TR, Chen B, et al. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 2005; 49(2): 708-20.
75. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol 2006; 13(5): 408-13.
76. Tsukamura M, sukamura S, Mizuno S, Nakano E. The mechanism of action of ethionamide. Am Rev Respir Dis 1964; 89: 933-5.
77. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47(12): 3799-805.
78. Dover LG, Alahari A, Gratraud P, et al. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother 2007; 51(3): 1055-63.
79. Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 2000; 275(36): 28326-31.
80. Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002; 277(15): 12824-9.
81. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE, III. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97(17): 9677-82.
82. Hanoulle X, Wieruszeski JM, Rousselot-Pailley P, et al. Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. J Antimicrob Chemother 2006; 58(4): 768-72.
83. Willand N, Dirie B, Carette X, et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009; 15(5): 537-44.
84. Frenois F, Baulard AR, Villeret V. Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis. Tuberculosis (Edinb ) 2006; 86(2): 110-4.
85. Frenois F, Engohang-Ndong J, Locht C, Baulard AR, Villeret V. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol Cell 2004; 16(2): 301-7.
86. Dover LG, Corsino PE, Daniels IR, et al. Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. J Mol Biol 2004; 340(5):1095-105.
87. Engohang-Ndong J, Baillat D, Aumercier M, et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol Microbiol 2004; 51(1):175-88.
88. Dalla Costa ER, Ribeiro MO, Silva MS, et al. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 2009; 9: 39.
89. Vilcheze C, Jacobs WR, Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 2007; 61: 35-50.
90. Cardoso RF, Cooksey RC, Morlock GP, et al. Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrob Agents Chemother 2004; 48(9): 3373-81.
91. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70(9): 4955-60.
92. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46(5): 1417-24.
93. Bottari B, Maccari R, Monforte F, Ottana R, Rotondo E, Vigorita MG. Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9. Bioorg Med Chem Lett 2000; 10(7): 657-60.
94. Bottari B, Maccari R, Monforte F, et al. Nickel(II) 2,6-diacetylpyridine bis(isonicotinoylhydrazonate) and bis(benzoylhydrazonate) complexes: structure and antimycobacterial evaluation. Part XI. Bioorg Med Chem 2001; 9(8): 2203-11.
95. Aboul-Fadl T, Mohammed FA, Hassan EA. Synthesis, antitubercular activity and pharmacokinetic studies of some Schiff bases derived from 1-alkylisatin and isonicotinic acid hydrazide (INH). Arch Pharm Res 2003; 26(10): 778-84.
96. Carvalho SA, da Silva EF, de Souza MV, Lourenco MC, Vicente FR. Synthesis and antimycobacterial evaluation of new transcinnamic acid hydrazide derivatives. Bioorg Med Chem Lett 2008; 18(2): 538-41.
97. Chakravarty D, Bose A, Bose S. Synthesis and anti-tubercular activity of isonicotinoyl and cyanoacetyl hydrazones. J Pharm Sci 1964; 53: 1036-9.
98. Lourenco MC, Ferreira ML, de Souza MV, Peralta MA, Vasconcelos TR, Henriques MG. Synthesis and anti-mycobacterial activity of (E)-N'- (monosubstituted-benzylidene)isonicotinohydrazide derivatives. Eur J Med Chem 2008; 43(6): 1344-7.
99. Maccari R, Ottana R, Monforte F, Vigorita MG. In vitro antimycobacterial activities of 2'-monosubstituted isonicotinohydrazides and their cyanoborane adducts. Antimicrob Agents Chemother 2002; 46(2): 294-9.
100. Almeida da Silva PE, Ramos DF, Bonacorso HG, et al. Synthesis and in vitro antimycobacterial activity of 3-substituted 5-hydroxy-5- trifluoro[chloro]methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles. Int J Antimicrob Agents 2008; 32(2): 139-44.
101. Pasqualoto KF, Ferreira EI, Santos-Filho OA, Hopfinger AJ. Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives. J Med Chem 2004; 47(15): 3755-64.
102. Sriram D, Yogeeswari P, Madhu K. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. Bioorg Med Chem Lett 2005; 15(20): 4502-5.
103. Sriram D, Yogeeswari P, Dhakla P, Senthilkumar P, Banerjee D, Manjashetty TH. 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. Bioorg Med Chem Lett 2009; 19(4): 1152-4.
104. Sriram D, Yogeeswari P, Yelamanchili PD. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis. Biomed Pharmacother 2009; 63(1): 36-9.
105. Strube RE, Stern KF. Isonicotinoyl hydrazine derivatives and their activity against Mycobacterium tuberculosis in the mouse. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1957; 46(12): 738-41.
106. Swamy BN, Suma TK, Rao GV, Reddy GC. Synthesis of isonicotinoylhydrazones from anacardic acid and their in vitro activity against Mycobacterium smegmatis. Eur J Med Chem 2007; 42(3): 420-4.
107. Scior T, Garces-Eisele SJ. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review. Curr Med Chem 2006; 13(18): 2205-19.
108. Oliveira JS, Vasconcelos IB, Moreira IS, Santos DS, Basso LA. Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents. Curr Drug Targets 2007; 8(3): 399-411.
109. Oliveira JS, Sousa EH, Basso LA, et al. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-transenoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. Chem Commun (Camb) 2004; (3): 312-3.
110. Tan L, Nielsen NH, Young DC, Trizna Z. Use of antimicrobial agents in consumer products. Arch Dermatol 2002; 138(8): 1082-6.
111. Jones RD, Jampani HB, Newman JL, Lee AS. Triclosan: a review of effectiveness and safety in health care settings. Am J Infect Control 2000; 28(2): 184-96.
112. Schweizer HP. Triclosan: a widely used biocide and its link to antibiotics. FEMS Microbiol Lett 2001; 202(1): 1-7.
113. McMurry LM, Oethinger M, Levy SB. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol Lett 1998; 166(2): 305-9.
114. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998; 394(6693): 531-2.
115. Heath RJ, Li J, Roland GE, Rock CO. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem 2000; 275(7): 4654-9.
116. McMurry LM, McDermott PF, Levy SB. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob Agents Chemother 1999; 43(3): 711-3.
117. Heath RJ, White SW, Rock CO. Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001; 40(6): 467-97.
118. Heath RJ, White SW, Rock CO. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl Microbiol Biotechnol 2002; 58(6): 695-703.
119. Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs 2004; 5(2): 146-53.
120. Zhang YM, Lu YJ, Rock CO. The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids 2004; 39(11): 1055-60.
121. Guillen J, Bernabeu A, Shapiro S, Villalain J. Location and orientation of Triclosan in phospholipid model membranes. Eur Biophys J 2004; 33(5): 448-53.
122. Villalain J, Mateo CR, Aranda FJ, Shapiro S, Micol V. Membranotropic effects of the antibacterial agent Triclosan. Arch Biochem Biophys 2001; 390(1): 128-36.
123. Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 2000; 39(26): 7645-50.
124. Kuo MR, Morbidoni HR, Alland D, et al. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 2003; 278(23): 20851-9.
125. Boyne ME, Sullivan TJ, amEnde CW, et al. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob Agents Chemother 2007; 51(10): 3562-7.
126. Sullivan TJ, Truglio JJ, Boyne ME, et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 2006; 1(1): 43-53.
127. Freundlich JS, Wang F, Vilcheze C, et al. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 2009; 4(2): 241-8.
128. Dormer BA. Isoxyl monotherapy. Antibiot Chemother 1970; 16: 105-7.
129. Gallen CS. Isoxyl: a review of the results of its use over a five-year period in the tuberculosis field service of a large urban area. Antibiot Chemother 1970; 16: 139-48.
130. Riska N, Pekkanen PS. Clinical experienceof Isoxyl. Acta Tuberc Pneumol Scand 1964; 45: 168-78.
131. Urbancik B. Clinical experience with thiocarlide (Isoxyl). Antibiot Chemother 1970; 16: 117-23.
132. Dover LG, Alahari A, Gratraud P, et al. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother 2007; 51(3): 1055-63.
133. Winder FG, Collins PB, Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J Gen Microbiol 1971; 66(3): 379-80.
134. Phetsuksiri B, Baulard AR, Cooper AM, et al. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother 1999; 43(5): 1042-51.
135. Phetsuksiri B, Jackson M, Scherman H, et al. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J Biol Chem 2003; 278(52): 53123-30.
136. Bhowruth V, Brown AK, Reynolds RC, et al. Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis. Bioorg Med Chem Lett 2006; 16(18): 4743-7.
137. Miller AB. Thiacetazone toxicity: a general review. Tubercle 1968; 49(Suppl): 54-6.
138. Nunn P, Porter J, Winstanley P. Thiacetazone--avoid like poison or use with care? Trans R Soc Trop Med Hyg 1993; 87(5): 578-82.
139. Okwera A, Johnson JL, Vjecha MJ, et al. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults. Int J Tuberc Lung Dis 1997; 1(5): 441-5.
140. Pearson CA. Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria. J Trop Med Hyg 1978; 81(12): 238-42.
141. Alahari A, Trivelli X, Guerardel Y, et al. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS ONE 2007; 2(12): e1343.
142. Alahari A, Alibaud L, Trivelli X, et al. Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. Mol Microbiol 2009; 71(5): 1263-77.
143. Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 2008; 62(5): 1037-45.
144. Hu Y, Coates AR, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12(1): 69-73.
145. Kim P, Zhang L, Manjunatha UH, et al. Structure-Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural Features Associated with Aerobic and Anaerobic Activities of 4- and 5-Nitroimidazoles. J Med Chem 2009; 52(5): 1329-44.
146. Bashiri G, Squire CJ, Baker EN, Moreland NJ. Expression, purification and crystallization of native and selenomethionine labeled Mycobacterium tuberculosis FGD1 (Rv0407) using a Mycobacterium smegmatis expression system. Protein Expr Purif 2007; 54(1): 38-44.
147. Bashiri G, Squire CJ, Moreland NJ, Baker EN. Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem 2008; 283(25): 17531-41.
148. Manjunatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CE, III. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother 2006; 50(10): 3350-4.
149. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322(5906): 1392-5.
150. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3(11): e466.